Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Syros Pharmaceuticals (SYRS)
NASDAQ:SYRS
Holding SYRS?
Track your performance easily
Earnings Data
Report Date
Mar 06, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.72Last Year’s EPS
-2.18Same Quarter Last Year
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 01, 2018
|% Change Since: -91.24%
|Next Earnings Date:Aug 07, 2018
Earnings Call Sentiment|Neutral
The earnings call conveyed a cautiously optimistic outlook, emphasizing the advancement of tamibarotene and its significant market potential, alongside improved financial metrics. However, the lack of revenue and decreased cash reserves present notable concerns.Company Guidance
During the Syros Pharmaceuticals third-quarter 2024 earnings call, the company provided guidance on several key metrics. The anticipated data readout from the SELECT-MDS-1 Phase III trial for tamibarotene is expected in mid-November, targeting a significant milestone for the treatment of higher-risk MDS patients with RARA gene overexpression. The total market opportunity for higher-risk MDS therapeutics in the U.S. by 2029 is projected to reach $1.6 billion, with tamibarotene potentially capturing over $800 million. Financially, Syros reported no revenue for Q3 2024, down from $3.8 million a year prior, primarily due to the termination of its collaboration with Pfizer. R&D expenses decreased to $20.5 million from $28.3 million, while G&A expenses fell to $5.7 million from $7.8 million. The company posted a net loss of $6.4 million or $0.16 per share, a significant improvement from a $40.1 million or $1.43 per share loss in Q3 2023. Syros had $58.3 million in cash and cash equivalents as of September 30, 2024, expected to fund operations into Q3 2025.Advancement of Tamibarotene as a New Standard of Care
Syros Pharmaceuticals is nearing a pivotal data readout from the SELECT-MDS-1 Phase III trial for tamibarotene, targeting higher-risk MDS patients with RARA gene overexpression. This milestone could transform the company's trajectory.
Significant Market Opportunity
The market opportunity for tamibarotene in the U.S. for patients with RARA overexpression is projected to be over $800 million by 2029, with the total market for higher-risk MDS therapeutics reaching approximately $1.6 billion.
Successful Completion of Futility Analysis
The SELECT-MDS-1 trial passed a prespecified futility analysis based on the primary endpoint, instilling confidence in the potential success of the trial.
Reduction in Net Loss
The net loss for the third quarter of 2024 was $6.4 million, a significant improvement from a net loss of $40.1 million in the third quarter of 2023.
---
SYRS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SYRS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | $2.51 | $2.52 | +0.40% |
| Jul 31, 2024 | $6.26 | $6.00 | -4.15% |
| May 14, 2024 | $5.06 | $5.43 | +7.31% |
| Mar 27, 2024 | $6.25 | $5.84 | -6.56% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Syros Pharmaceuticals (SYRS) report earnings?
Syros Pharmaceuticals (SYRS) is schdueled to report earning on Mar 06, 2025, TBA Not Confirmed.
What is Syros Pharmaceuticals (SYRS) earnings time?
Syros Pharmaceuticals (SYRS) earnings time is at Mar 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SYRS EPS forecast?
SYRS EPS forecast for the fiscal quarter 2024 (Q4) is -0.72.
---